Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.

@article{Blick2007CetuximabAR,
  title={Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.},
  author={Stephanie K. A. Blick and Lesley J. Scott},
  journal={Drugs},
  year={2007},
  volume={67 17},
  pages={
          2585-607
        }
}
Cetuximab (Erbitux) is a human-mouse chimeric monoclonal antibody, which competitively binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) to inhibit dimerisation and, subsequently, inhibit tumour growth and metastasis. In the EU and the US, cetuximab has been approved for use with concomitant radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) and in combination with irinotecan for the treatment of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Anti - epidermal growth factor treated by cetuximab plus chemotherapy

  • G Spitzer, I Zackon, P Stella
  • Br J Cancer
  • 2007

Bevacizumab : a review

  • KA Lyseng-Williamson, DM Robinson
  • Lancet Oncol
  • 2007

Cetuximab an EXTREMEly important addition in 1 : i 18 - 9 SCCHN

  • M Le Fevre
  • Inpharma
  • 2007

Cetuximab for monstrate cost - effectiveness of new compounds . Pharma - the treatment of colorectal cancer

  • H Mason, A Marshall, M Jones-Lee, H Wilke, R Glynne-Jones, J Thaler
  • N Eng J Med
  • 2007

Clinical practice and neck cancer with concurrent radiochemotherapy in vivo . guidelines in oncology : rectal cancer . Version 1 2008 [ online ]

  • J Bernier, FY Feng, CA Lopez, DP Normolle
  • Clin Cancer Res
  • 2007

ESMO minimum implications

  • NJ Meropol, KA Schulman, Van Cutsem EJD, J Oliveira, VV Kataja
  • J Clin Oncol
  • 2007

Hypomagnesemia in patients ( PK ) , pharmacodynamic ( PD ) and efficacy data [ abstract no . with stage IV colorectal cancer treated with cetuximab as a 4037 ]

  • AF Sobrero, L Fehrenbacher, +5 authors JP Spano
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…